Nivolumab (Opdivo®) for advanced renal cell carcinoma

Assessment Status Assessment Process Complete
Drug Nivolumab
Brand Opdivo®
Indication Is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults
Assessment Process
Rapid review commissioned 27/04/2016
Rapid review completed 16/05/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 28/10/2016
NCPE assessment completed 28/03/2017
NCPE assessment outcome Reimbursement Not Recommended at the Submitted Price

Technical Summary

The HSE has approved reimbursement following confidential price negotiations October 2017.